Fig S1. Workflow of the clinical and genomic studies. All MRXLS probands underwent custom-designed high-resolution aCGH which has a 1 probe/800 bp resolution. Then all patients underwent short-read GS (37X coverage). Patients who were found to have CGR on aCGH and GS underwent long-read on either Promethion or MinION Flow cells [ONT (3X-40X coverage) or PacBio HiFi (10X-20X coverage) and/or Optical Mapping. aCGH: array Comparative Genomic Hybridization, bp: base pair, MRXLS: *MECP2* Duplication Syndrome, GS: Genome Sequencing, ONT: Oxford Nanopore Technologies.




Fig S2: CNV size and gene content across Xq26-Xq28 in 125 unrelated probands. a. Individual CNVs coordinates mapped by custom aCGH are grouped by genomic structure, \* indicates apparently simple duplications with structures that are not completely solved. Proband identification is shown on the left. Red bars indicate duplicated region; blue bars indicate triplicated region. Blue arrows indicate *MECP2* is triplicated. Genes shown below are disease causing genes as per OMIM. Smallest Region of Overlap (SRO) is shown as the gray bar b. Reported *MECP2* cis-regulatory elements (CRE) are indicated as F11, F16, F17, F21, F3, F13.<sup>1,2</sup> Tandem duplication group includes individuals carrying unsolved duplications as detected by aCGH.







Fig S3. Transcriptomic heterogeneity amongst MRXLS patient-derived fibroblast cells. RNA from fibroblasts from 18 MRXLS individuals from the clinical cohort was collected and processed for RNA-sequencing transcriptomic analyses. Patient lines were collected as triplicate RNA preparations. a. Normalized *MECP2* expression from RNA-sequencing data. b. Normalized *IRAK1* expression from RNA-sequencing data. c. Gene expression along Xq28. Expressed genes are ordered from more centromeric (left) to telomeric (right) within the maximal genomic region spanning the cohort of samples collected. Samples are scaled by column, and rows are clustered using hierarchical clustering with Euclidean distance. d. Principal component representation of global gene expression changes between MRXLS and unaffected control lines.



- 1. Liu, J., and Francke, U. (2006). Identification of cis-regulatory elements for MECP2 expression. Hum Mol Genet *15*, 1769-1782. 10.1093/hmg/ddl099.
- 2. Shao, Y., Bajikar, S.S., Tirumala, H.P., Gutierrez, M.C., Wythe, J.D., and Zoghbi, H.Y. (2021). Identification and characterization of conserved noncoding cis-regulatory elements that impact Mecp2 expression and neurological functions. Genes Dev *35*, 489-494. 10.1101/gad.345397.120.